ReviewDrugs2016

Management of NSCLC Disease Progression After First-Line EGFR Tyrosine Kinase Inhibitors: What Are the Issues and Potential Therapies?

Raffaele Califano et al.PubMed ↗Publisher ↗

No numbers read from the abstract.